spec sheet9 rows
Ethomersol is a benzimidazole actoprotector and antihypoxant (5-ethoxy-2-ethylthio-1H-benzimidazole) developed within the Soviet military-medical pharmacology school as the lipophilic 5-ethoxy analog of bemitil. As an actoprotector it is designed to raise and sustain physical and mental work capacity under adverse conditions without increasing oxygen consumption or heat production, placing it in the same "synthetic adaptogen" class as bemitil and bromantane. It belongs to the aliphatic and cyclic aminothiol lineage synthesized by F.Yu. Rachinsky and studied under V.M. Vinogradov at the S.M. Kirov Military Medical Academy, alongside gutimin, amtizole and bemitil. Rather than acting on a classical receptor, it normalizes cellular energy metabolism during oxygen deficit, acts as a direct antioxidant, and stimulates adaptive protein synthesis, giving it combined antihypoxic, antioxidant, energotropic and reparative activity documented in preclinical models of hypoxia, toxic injury, and traumatic brain injury.
- Raises physical work capacity and endurance under stress without increasing oxygen use or heat
- Antihypoxant; helps cells produce energy when oxygen is scarce
- Strong direct antioxidant; curbs lipid peroxidation and lifts glutathione in brain and liver
- Neuroprotective in models of traumatic brain injury and acute hypoxia
- Speeds tissue repair, including liver regeneration after partial hepatectomy
- Non-depleting, adaptogen-style profile with no classic stimulant crash
- Class members can cause GI upset or overstimulation
Overview
Ethomersol is essentially bemitil's more lipophilic cousin; that extra ethoxy group is why it soaks so well into brain, heart and muscle, and in the head to head rat work it pretty much out-performed metaprot on the antioxidant and actoprotector endpoints. The appeal is the profile; it lifts endurance without cranking oxygen use or body heat the way a classic stimulant does, so it reads as a non-depleting, adaptogen-style booster that also props up glutathione, curbs lipid peroxidation and speeds tissue repair after hypoxic or toxic hits.
It carries the same energy-sparing, "help the cell make ATP when oxygen is short" logic as the rest of the aminothiol family, with a genuinely strong neuroprotective signal in the brain-trauma models. It is an investigational Russian-lineage compound and most of the evidence is preclinical, so it is best treated as an experimental antihypoxant rather than a daily driver; that said, for anyone into the actoprotector class it is hands down one of the cleaner-looking members on paper.
Mechanism
Ethomersol (5-ethoxy-2-ethylthio-1H-benzimidazole) is a benzimidazole aminothiol in the actoprotector/antihypoxant class rather than a receptor , so it works through metabolic rather than mechanisms. It normalizes cellular energy metabolism when oxygen is limited by improving the efficiency of oxidative phosphorylation and supporting gluconeogenesis, so tissues generate ATP with less oxygen (an antihypoxic, energy-sparing action that also lowers overall tissue oxygen demand).
It is a direct antioxidant: in brain and liver it inhibits Fe2+-induced, ascorbate- and NADPH-dependent lipid peroxidation, reduces conjugated dienes and malondialdehyde, and raises thiols, glutathione and antioxidant-enzyme activity. Like its parent bemitil, it stimulates adaptive RNA and protein synthesis, which underlies its reparative effects on liver regeneration and its recovery of function after hypoxic, toxic (organophosphate, ethylene-glycol) or traumatic injury; part of its hepatoprotective and immunomodulatory action appears to be thymus-dependent. Being , it distributes widely and accumulates in blood, brain, heart, kidneys, lungs and adipose tissue with repeated (course) dosing.
receptor fingerprint
oxidative metabolism / gluconeogenesisenhances efficiency
Fe2+-induced lipid peroxidation (ascorbate/NADPH-dependent)inhibits
Glutathione / thiol antioxidant enzyme systemupregulates
Adaptive RNA and protein synthesisstimulates
Tissue oxygen consumptionreduces
Gluconeogenesis / lactate resynthesisactivates (via induced enzyme synthesis)
enzyme & structural protein synthesisupregulates
Antioxidant enzymes (SOD, catalase, glutathione system)induces
Thymus-dependent immune functionmodulates
Voltage- and receptor-dependent calcium channelsblocks
Erythrocyte membrane deformabilityimproves
Hemoglobin oxygen affinityreduces
Safetyrisks and cautions, not medical advice
Human safety data come mainly from older Russian and Soviet military-medicine research, so the profile is not characterized to Western standards, and it is not an approved medicine in most countries. As a metabolic, stimulant-adjacent actoprotector, overstimulation or sleep disruption is plausible with heavy use, and competitive athletes should note that actoprotectors are watched by anti-doping bodies. Long-term human data are limited. It is not risk-free, but preclinical work reports low toxicity and a hepatoprotective rather than hepatotoxic profile.
Subjective profileweighing the evidence above
A well-characterized-in-animals antihypoxant and actoprotector; the lipophilic sibling of bemitil that matched or beat metaprot on antioxidant and performance endpoints in rat studies, with a clean non-depleting profile on paper, but still investigational and preclinical in humans.
Resources
This entry is here for reference.
Research
- 1996first citedChanges in the morphofunctional status of the liver in rats with acute tetrachloromethane poiso…
- 2012most recentProtective effects of metaprot and ethomerzol in carbophos intoxications
- 1.Protective effects of metaprot and ethomerzol in carbophos intoxications
- 2.Distribution of ethomerzol in organ and tissue of rats after single and course treatment
- 3.The significance of individual resistance to hypoxia for correction of the consequences of craniocerebral trauma
- 4.Ethomerzol as an antioxidant
- 5.Effects of bemethyl, ethomersol, and yakton on the liver regeneration after partial hepatectomy
- 6.The protective action of ethomersol in acute hypobaric hypoxia and during the recovery after it
- 7.The pharmacology of actoprotectors: practical application for improvement of mental and physical performance
- 8.Changes in the morphofunctional status of the liver in rats with acute tetrachloromethane poisoning and their correction with antihypoxants, antioxidants and actoprotectors
8 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
What is ethomersol used for?
It is an actoprotector and antihypoxant intended to boost physical and mental work capacity and to protect tissue against hypoxia, oxidative stress, toxic injury and traumatic brain injury; in practice the evidence base is preclinical.
How does ethomersol work?
It is a benzimidazole aminothiol that normalizes energy metabolism under low oxygen, scavenges free radicals and inhibits lipid peroxidation, raises glutathione, and stimulates adaptive protein synthesis to speed repair; it is a metabolic drug rather than a receptor agonist.
How is it different from bemitil?
Ethomersol is the 5-ethoxy analog of bemitil (metaprot); the extra ethoxy group makes it more lipophilic so it distributes into brain, heart and muscle, and it outperformed metaprot on some antioxidant and actoprotector endpoints in rats.
Is ethomersol well researched?
It has a solid preclinical base from Russian military-medical pharmacology spanning hypoxia, brain trauma, liver regeneration and toxic exposures, but controlled human trials are limited, so it is best treated as investigational.
What are the main side effects?
Its human safety profile is not well defined; class effects can include GI upset or overstimulation, and being lipophilic it accumulates in tissue with repeated dosing.
Adverse effects
- Class members can cause GI upset or overstimulation
Notes and cautions
- Investigational; nearly all evidence is preclinical (rat) research
- Not an approved medicine outside the Russian-sphere setting
- Human safety and dosing are not well characterized
- As a lipophilic thiobenzimidazole it accumulates in tissue with repeated dosing